Incorporation of Ruxolitinib in the Management of Refractory/Relapsed Hodgkin Lymphoma: Where Do We Stand?
作者信息
Al Sharie Ahmed H, Abu Mousa Balqis M, Alomari Ahmad O
机构信息
Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan.
出版信息
Clin Hematol Int. 2023 Aug 28;5(4):1-4. doi: 10.46989/001c.87501. eCollection 2023.
Abstract
摘要
相似文献
1
Incorporation of Ruxolitinib in the Management of Refractory/Relapsed Hodgkin Lymphoma: Where Do We Stand?芦可替尼在难治性/复发性霍奇金淋巴瘤治疗中的应用：我们目前的进展如何？
Clin Hematol Int. 2023 Aug 28;5(4):1-4. doi: 10.46989/001c.87501. eCollection 2023.
2
A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.一项评估口服 JAK1/JAK2 抑制剂芦可替尼治疗晚期复发/难治性霍奇金淋巴瘤的 II 期研究。
Haematologica. 2018 May;103(5):840-848. doi: 10.3324/haematol.2017.180554. Epub 2018 Jan 19.
3
Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma.芦可替尼对霍奇金淋巴瘤有活性，但对原发性纵隔大 B 细胞淋巴瘤没有活性。
BMC Cancer. 2019 Nov 10;19(1):1080. doi: 10.1186/s12885-019-6303-z.
4
JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO).芦可替尼治疗复发或难治性经典型霍奇金淋巴瘤的 JAK 抑制作用：一项开放标签、多中心、Ⅱ期临床试验（JeRiCHO）的最终结果。
Eur J Haematol. 2022 Dec;109(6):728-735. doi: 10.1111/ejh.13859. Epub 2022 Oct 3.
5
The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience.吉西他滨、地塞米松和顺铂化疗治疗复发/难治性 NHL 和 HL 患者的效果：单中心经验。
J Oncol Pharm Pract. 2020 Dec;26(8):1857-1863. doi: 10.1177/1078155220905654. Epub 2020 Feb 25.
6
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.皮下注射依鲁替尼在复发或难治性 B 细胞非霍奇金淋巴瘤患者中的剂量递增：一项开放标签、1/2 期研究。
Lancet. 2021 Sep 25;398(10306):1157-1169. doi: 10.1016/S0140-6736(21)00889-8. Epub 2021 Sep 8.
7
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.自体移植后复发/难治性霍奇金淋巴瘤中维布妥昔单抗治疗：荟萃分析与历史数据对比
Curr Med Res Opin. 2015 May;31(5):993-1001. doi: 10.1185/03007995.2015.1030378. Epub 2015 Apr 9.
8
Gemcitabine-Based Treatment in Poor-Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma--a Multicenter Polish Experience.基于吉西他滨的治疗方案用于复发难治性霍奇金淋巴瘤和非霍奇金淋巴瘤的预后不良患者——一项波兰多中心经验。
Adv Clin Exp Med. 2015 Sep-Oct;24(5):783-9. doi: 10.17219/acem/34795.
9
High dose chemotherapy and autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: Emerging questions, newer agents, and changing paradigm.高剂量化疗及自体干细胞移植治疗复发或难治性霍奇金淋巴瘤：新出现的问题、新型药物及不断变化的模式
Hematol Oncol Stem Cell Ther. 2017 Dec;10(4):272-276. doi: 10.1016/j.hemonc.2017.05.010. Epub 2017 Jun 13.
10
The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.欧洲药品管理局对用于治疗复发或难治性CD30+霍奇金淋巴瘤或系统性间变性大细胞淋巴瘤成年患者的本妥昔单抗（安适利）的审评：人用药品委员会科学评估总结
Oncologist. 2016 Jan;21(1):102-9. doi: 10.1634/theoncologist.2015-0276. Epub 2015 Nov 30.
本文引用的文献
1
Genetic lesions and targeted therapy in Hodgkin lymphoma.霍奇金淋巴瘤中的基因损伤与靶向治疗
Ther Adv Hematol. 2023 Jan 12;14:20406207221149245. doi: 10.1177/20406207221149245. eCollection 2023.
2
JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO).芦可替尼治疗复发或难治性经典型霍奇金淋巴瘤的 JAK 抑制作用：一项开放标签、多中心、Ⅱ期临床试验（JeRiCHO）的最终结果。
Eur J Haematol. 2022 Dec;109(6):728-735. doi: 10.1111/ejh.13859. Epub 2022 Oct 3.
3
Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies.经典型霍奇金淋巴瘤治疗的最新进展：新型治疗方法的时代。
Blood Cancer J. 2021 Jul 9;11(7):126. doi: 10.1038/s41408-021-00518-z.
4
Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma.芦可替尼对霍奇金淋巴瘤有活性，但对原发性纵隔大 B 细胞淋巴瘤没有活性。
BMC Cancer. 2019 Nov 10;19(1):1080. doi: 10.1186/s12885-019-6303-z.
5
A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.一项评估口服 JAK1/JAK2 抑制剂芦可替尼治疗晚期复发/难治性霍奇金淋巴瘤的 II 期研究。
Haematologica. 2018 May;103(5):840-848. doi: 10.3324/haematol.2017.180554. Epub 2018 Jan 19.
Zotero 插件